Felix Kh Chun

List of Publications by Year
in descending order

Version: 2024-02-01

177 papers	9,542 citations	25034 57 h-index	45317 90 g-index
191 all docs	191 docs citations	191 times ranked	7397 citing authors

#	Article	IF	Citations
1	Complications and Other Surgical Outcomes Associated with Extended Pelvic Lymphadenectomy in Men with Localized Prostate Cancer. European Urology, 2006, 50, 1006-1013.	1.9	341
2	Evaluation of Prostate Cancer Detection with Ultrasound Real-Time Elastography: A Comparison with Step Section Pathological Analysis after Radical Prostatectomy. European Urology, 2008, 54, 1354-1362.	1.9	226
3	Validation of a Nomogram Predicting the Probability of Lymph Node Invasion among Patients Undergoing Radical Prostatectomy and an Extended Pelvic Lymphadenectomy. European Urology, 2006, 49, 1019-1027.	1.9	215
4	Development and Internal Validation of a Nomogram Predicting the Probability of Prostate Cancer Gleason Sum Upgrading Between Biopsy and Radical Prostatectomy Pathology. European Urology, 2006, 49, 820-826.	1.9	188
5	High Incidence of Prostate Cancer Detected by Saturation Biopsy after Previous Negative Biopsy Series. European Urology, 2006, 50, 498-505.	1.9	178
6	Validation of a Nomogram for Prediction of Side Specific Extracapsular Extension at Radical Prostatectomy. Journal of Urology, 2006, 175, 939-944.	0.4	163
7	Prognostic Role and HER2 Expression of Circulating Tumor Cells in Peripheral Blood of Patients Prior to Radical Cystectomy: A Prospective Study. European Urology, 2012, 61, 810-817.	1.9	163
8	Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU International, 2006, 98, 788-793.	2.5	162
9	Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. European Urology, 2009, 56, 659-668.	1.9	161
10	Critical Assessment of Ideal Nodal Yield at Pelvic Lymphadenectomy to Accurately Diagnose Prostate Cancer Nodal Metastasis in Patients Undergoing Radical Retropubic Prostatectomy. Urology, 2007, 69, 147-151.	1.0	156
11	Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. European Urology, 2014, 66, 156-163.	1.9	156
12	Death Certificates Are Valid for the Determination of Cause of Death in Patients With Upper and Lower Tract Urothelial Carcinoma. European Urology, 2012, 61, 854-855.	1.9	152
13	Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer. European Urology, 2011, 60, 1045-1054.	1.9	148
14	Clinical Evaluation of the PCA3 Assay in Guiding Initial Biopsy Decisions. Journal of Urology, 2011, 185, 2119-2125.	0.4	136
15	Anatomic radical retropubic prostatectomyâ€"long-term recurrence-free survival rates for localized prostate cancer. World Journal of Urology, 2006, 24, 273-280.	2.2	134
16	Comparison of stage migration patterns between Europe and the USA: an analysis of 11â€ƒ350 men treated with radical prostatectomy for prostate cancer. BJU International, 2008, 101, 1513-1518.	2.5	134
17	Nomogram Predicting the Probability of Early Recurrence After Radical Prostatectomy for Prostate Cancer. Journal of Urology, 2009, 181, 601-608.	0.4	129
18	Critical Assessment of Preoperative Urinary Prostate Cancer Antigen 3 on the Accuracy of Prostate Cancer Staging. European Urology, 2011, 59, 96-105.	1.9	127

#	Article	IF	Citations
19	Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU International, 2006, 98, 329-334.	2.5	126
20	Circulating Prostate Tumor Cells Detected by Reverse Transcription-PCR in Men with Localized or Castration-Refractory Prostate Cancer: Concordance with CellSearch Assay and Association with Bone Metastases and with Survival. Clinical Chemistry, 2009, 55, 765-773.	3.2	122
21	Pathological results and rates of treatment failure in highâ€risk prostate cancer patients after radical prostatectomy. BJU International, 2011, 107, 765-770.	2.5	120
22	25-Year Prostate Cancer Control and Survival Outcomes: A 40-Year Radical Prostatectomy Single Institution Series. Journal of Urology, 2006, 176, 569-574.	0.4	119
23	Development and External Validation of an Extended 10-Core Biopsy Nomogram. European Urology, 2007, 52, 436-445.	1.9	114
24	Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma. Journal of Urology, 2012, 188, 398-404.	0.4	114
25	Initial Prostate Biopsy: Development and Internal Validation of a Biopsy-specific Nomogram Based on the Prostate Cancer Antigen 3 Assay. European Urology, 2013, 63, 201-209.	1.9	114
26	A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. BJU International, 2007, 99, 794-800.	2.5	111
27	Radical prostatectomy improves progressionâ€free and cancerâ€specific survival in men with lymph node positive prostate cancer in the prostateâ€specific antigen era: a confirmatory study. BJU International, 2011, 107, 1755-1761.	2.5	105
28	Impact of Smoking and Smoking Cessation on Oncologic Outcomes in Primary Nonâ€“muscle-invasive Bladder Cancer. European Urology, 2013, 63, 724-732.	1.9	105
29	Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU International, 2006, 98, 544-548.	2.5	104
30	Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy. European Urology, 2013, 64, 456-464.	1.9	101
31	Natural history of surgically treated high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 163.e7-163.e13.	1.6	101
32	Local Therapy Improves Survival in Metastatic Prostate Cancer. European Urology, 2017, 72, 118-124.	1.9	100
33	Impact of Age and Comorbidities on Long-term Survival of Patients with High-risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-institutional Competing-risks Analysis. European Urology, 2013, 63, 693-701.	1.9	98
34	Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. European Urology, 2013, 63, 1082-1090.	1.9	98
35	Currently used criteria for active surveillance in men with lowâ€risk prostate cancer. Cancer, 2008, 113, 2068-2072.	4.1	96
36	External Validation of Urinary PCA3-Based Nomograms to Individually Predict Prostate Biopsy Outcome. European Urology, 2010, 58, 727-732.	1.9	96

#	Article	IF	Citations
37	Optimizing Performance and Interpretation of Prostate Biopsy: A Critical Analysis of the Literature. European Urology, 2010, 58, 851-864.	1.9	96
38	Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis. European Urology, 2008, 54, 1373-1378.	1.9	91
39	Prostate Cancer Nomograms: An Update. European Urology, 2006, 50, 914-926.	1.9	89
40	Detection of circulating tumour cells in peripheral blood of patients with advanced nonâ€metastatic bladder cancer. BJU International, 2011, 107, 1668-1675.	2.5	89
41	Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2â€“10 ng/ml. PLoS ONE, 2013, 8, e67687.	2.5	87
42	Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer, 2008, 113, 701-709.	4.1	86
43	Percentage of Positive Biopsy Cores Can Improve the Ability to Predict Lymph Node Invasion in Patients Undergoing Radical Prostatectomy and Extended Pelvic Lymph Node Dissection. European Urology, 2007, 51, 1573-1581.	1.9	84
44	Biochemical Recurrence After Radical Prostatectomy: Multiplicative Interaction Between Surgical Margin Status and Pathological Stage. Journal of Urology, 2010, 184, 1341-1346.	0.4	84
45	Prostate volume and adverse prostate cancer features: Fact not artifact. European Journal of Cancer, 2007, 43, 2669-2677.	2.8	82
46	Initial Biopsy Outcome Predictionâ€”Head-to-Head Comparison of a Logistic Regression-Based Nomogram versus Artificial Neural Network. European Urology, 2007, 51, 1236-1243.	1.9	79
47	Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. European Journal of Cancer, 2007, 43, 536-543.	2.8	77
48	Predictors of cancerâ€specific mortality after disease recurrence following radical cystectomy. BJU International, 2013, 111, E30-6.	2.5	77
49	Development and External Validation of an Extended Repeat Biopsy Nomogram. Journal of Urology, 2007, 177, 510-515.	0.4	75
50	Head-to-Head Comparison of the Three Most Commonly Used Preoperative Models for Prediction of Biochemical Recurrence After Radical Prostatectomy. European Urology, 2010, 57, 562-568.	1.9	69
51	Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. European Urology, 2012, 61, 237-242.	1.9	69
52	Frozen Section for the Management of Intraoperatively Detected Palpable Tumor Lesions During Nerve-Sparing Scheduled Radical Prostatectomy. European Urology, 2006, 49, 1011-1018.	1.9	67
53	Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thrombosis and Haemostasis, 2009, 101, 1147-1155.	3.4	67
54	A Nomogram for Staging of Exclusive Nonobturator Lymph Node Metastases in Men with Localized Prostate Cancer. European Urology, 2007, 51, 112-120.	1.9	66

#	Article	IF	Citations
55	Obesity is Associated with Worse Outcomes in Patients with T1 High Grade Urothelial Carcinoma of the Bladder. Journal of Urology, 2013, 190, 480-486.	0.4	66
56	Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients. BJU International, 2006, 98, 1204-1209.	2.5	62
57	Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. World Journal of Urology, 2011, 29, 473-480.	2.2	62
58	Impact of Surgical Volume on the Rate of Lymph Node Metastases in Patients Undergoing Radical Prostatectomy and Extended Pelvic Lymph Node Dissection for Clinically Localized Prostate Cancer. European Urology, 2008, 54, 794-804.	1.9	61
59	Tumor Size Improves the Accuracy of TNM Predictions in Patients with Renal Cancer. European Urology, 2006, 50, 521-529.	1.9	60
60	A comparative performance analysis of total prostateâ€specific antigen, percentage free prostateâ€specific antigen, prostateâ€specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. BJU International, 2012, 109, 1627-1635.	2.5	59
61	The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-GuÃ©rin Instillation Therapy on the Quality of Life in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Prospective, Randomized, Phase II Trial. Journal of Urology, 2013, 190, 857-862.	0.4	58
62	Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World Journal of Urology, 2013, 31, 1029-1036.	2.2	55
63	Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. International Journal of Cancer, 2007, 120, 1465-1471.	5.1	54
64	Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. Annals of Surgical Oncology, 2012, 19, 4337-4344.	1.5	53
65	Transurethral Holmium Laser Enucleation Versus Transurethral Resection of the Prostate and Simple Open Prostatectomyâ€"Which Procedure is Faster?. Journal of Urology, 2012, 187, 1608-1613.	0.4	51
66	Biomolecular Predictors of Urothelial Cancer Behavior and Treatment Outcomes. Current Urology Reports, 2012, 13, 122-135.	2.2	51
67	External validation of the updated briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. Prostate, 2013, 73, 211-218.	2.3	51
68	Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1259-1266.	1.6	50
69	Assessment of Cancer Control Outcomes in Patients With High-risk Renal Cell Carcinoma Treated With Partial Nephrectomy. Urology, 2012, 80, 347-353.	1.0	49
70	Impact of Preoperative Anemia on Oncologic Outcomes of Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. Journal of Urology, 2014, 191, 316-322.	0.4	49
71	Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. International Journal of Cancer, 2006, 118, 1234-1240.	5.1	48
72	Role of nomograms for prostate cancer in 2007. World Journal of Urology, 2007, 25, 131-142.	2.2	48

#	Article	IF	Citations
73	Accurate preoperative prediction of nonâ€organâ€confined bladder urothelial carcinoma at cystectomy. BJU International, 2013, 111, 404-411.	2.5	48
74	Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy. European Urology, 2013, 63, 371-378.	1.9	47
75	The 2002 AJCC pT2 Substages Confer No Prognostic Information on the Rate of Biochemical Recurrence After Radical Prostatectomy. European Urology, 2006, 49, 273-279.	1.9	45
76	Impact of Smoking on Outcomes of Patients with a History of Recurrent Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2012, 188, 2120-2128.	0.4	45
77	Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. International Journal of Cancer, 2007, 121, 791-795.	5.1	44
78	National Trends and Disparities in the Use of Minimally Invasive Adult Pyeloplasty. Journal of Urology, 2012, 188, 913-918.	0.4	44
79	Subclassification of pT3 Urothelial Carcinoma of the Renal Pelvicalyceal System is Associated With Recurrence-Free and Cancer-Specific Survival: Proposal for a Revision of the Current TNM Classification. European Urology, 2012, 62, 224-231.	1.9	44
80	A MULTICENTER CLINICAL TRIAL ON THE USE OF (â€“5, â€“7) PRO PROSTATE SPECIFIC ANTIGEN. Journal of Urology, 2005, 174, 2150-2153.	0.4	41
81	Marked Gene Transcript Level Alterations Occur Early During Radical Prostatectomy. European Urology, 2008, 53, 333-346.	1.9	40
82	[F18]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: Preliminary results from a prospective histology-based study. European Journal of Cancer, 2010, 46, 449-455.	2.8	39
83	Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. BJU International, 2008, 102, 253-258.	2.5	38
84	Management of erectile dysfunction after radical prostatectomy in 2007. World Journal of Urology, 2007, 25, 143-148.	2.2	37
85	Prediction of patientâ€specific risk and percentile cohort risk of pathological stage outcome using continuous prostateâ€specific antigen measurement, clinical stage and biopsy Gleason score. BJU International, 2011, 107, 1562-1569.	2.5	36
86	The Effect of Resident Involvement on Perioperative Outcomes in Transurethral Urologic Surgeries. Journal of Surgical Education, 2015, 72, 1018-1025.	2.5	36
87	Plasma tissue factor antigen in localized prostate cancer: Distribution, clinical significance and correlation with haemostatic activation markers. Thrombosis and Haemostasis, 2007, 97, 464-470.	3.4	35
88	Systematic Assessment of the Ability of the Number and Percentage of Positive Biopsy Cores to Predict Pathologic Stage and Biochemical Recurrence after Radical Prostatectomy. European Urology, 2007, 52, 733-745.	1.9	35
89	Prevalence of a Tertiary Gleason Grade and Its Impact on Adverse Histopathologic Parameters in a Contemporary Radical Prostatectomy Series. European Urology, 2009, 55, 394-403.	1.9	35
90	Head to Head Comparison of Nomograms Predicting Probability of Lymph Node Invasion of Prostate Cancer in Patients Undergoing Extended Pelvic Lymph Node Dissection. Urology, 2012, 79, 546-551.	1.0	34

#	Article	IF	Citations
91	Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. BJU International, 2007, 100, 528-532.	2.5	33
92	Prediction of sexual function after radical prostatectomy. Cancer, 2009, 115, 3150-3159.	4.1	33
93	Prognosis of patients with pelvic lymph node (<scp>LN</scp>) metastasis after radical prostatectomy: Value of extranodal extension and size of the largest <scp>LN</scp> metastasis. BJU International, 2014, 114, 503-510.	2.5	33
94	Evidence from the â€˜PROspective MulticEnTer RadIcal Cystectomy Series 2011 (PROMETRICS 2011)â€™ Study: How are Preoperative Patient Characteristics Associated with Urinary Diversion Type After Radical Cystectomy for Bladder Cancer?. Annals of Surgical Oncology, 2015, 22, 1032-1042.	1.5	33
95	Percent free prostateâ€specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower. Cancer, 2008, 113, 2695-2703.	4.1	32
96	Impact of Clinical and Histopathological Parameters on Disease Specific Survival in Patients with Collecting Duct Renal Cell Carcinoma: Development of a Disease Specific Risk Model. Journal of Urology, 2013, 190, 458-463.	0.4	31
97	Genderâ€specific effect of smoking on upper tract urothelial carcinoma outcomes. BJU International, 2013, 112, 623-637.	2.5	31
98	Effect of Body Mass Index on Histopathologic Parameters: Results of Large European Contemporary Consecutive Open Radical Prostatectomy Series. Urology, 2009, 73, 615-619.	1.0	30
99	<scp>PTEN</scp> deletions are related to disease progression and unfavourable prognosis in early bladder cancer. Histopathology, 2013, 63, 670-677.	2.9	30
100	Predictors of survival in patients with disease recurrence after radical nephroureterectomy. BJU International, 2014, 113, 911-917.	2.5	28
101	MALDI imagingâ€“based identification of prognostically relevant signals in bladder cancer using large-scale tissue microarrays1These authors contributed equally to this work.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1225-1233.	1.6	27
102	Protocol-based Active Surveillance for Low-risk Prostate Cancer: Anxiety Levels in Both Men and Their Partners. Urology, 2012, 80, 564-569.	1.0	26
103	Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. BJU International, 2013, 111, 74-84.	2.5	26
104	Assessment of Pathological Prostate Cancer Characteristics in Men with Favorable Biopsy Features on Predominantly Sextant Biopsy. European Urology, 2009, 55, 617-628.	1.9	25
105	Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients. Journal of Cancer Research and Clinical Oncology, 2011, 137, 811-819.	2.5	25
106	Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma. International Journal of Cancer, 2013, 132, 2948-2955.	5.1	25
107	A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer. BJU International, 2008, 101, 556-560.	2.5	24
108	Contemporary Prostate Cancer Prevalence among T1c Biopsy-Referred Men with a Prostate-Specific Antigen Level â‰¤ 4.0ng per Milliliter. European Urology, 2008, 53, 750-757.	1.9	24

#	Article	IF	Citations
109	Unilateral Prostate Cancer Cannot be Accurately Predicted in Low-Risk Patients. International Journal of Radiation Oncology Biology Physics, 2010, 77, 784-787.	0.8	24
110	Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment. British Journal of Cancer, 2014, 111, 213-219.	6.4	24
111	Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. European Urology, 2014, 66, 439-446.	1.9	24
112	High Radical Prostatectomy Surgical Volume is Related to Lower Radical Prostatectomy Total Hospital Charges. European Urology, 2006, 50, 58-63.	1.9	23
113	Zonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical Recurrence after Radical Prostatectomy. European Urology, 2007, 51, 949-955.	1.9	23
114	Molecular Cancer Phenotype in Normal Prostate Tissue. European Urology, 2009, 55, 885-891.	1.9	23
115	Thermal Ablation of Renal Tumors. Deutsches Ärzteblatt International, 2015, 112, 412-8.	0.9	23
116	Wound dehiscence in a sample of 1Â776 cystectomies: identification of predictors and implications for outcomes. BJU International, 2016, 117, E95-E101.	2.5	23
117	The Impact of Resident Involvement in Male One-stage Anterior Urethroplasties. Urology, 2015, 85, 937-941.	1.0	21
118	Populationâ€Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients. Prostate, 2017, 77, 105-113.	2.3	21
119	Body mass index does not improve the ability to predict biochemical recurrence after radical prostatectomy. European Journal of Cancer, 2007, 43, 375-382.	2.8	20
120	Outcomes Research: A Methodologic Review. European Urology, 2006, 50, 218-224.	1.9	19
121	Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. BJU International, 2007, 100, 37-41.	2.5	19
122	Prostate-Specific Antigen Improves the Ability of Clinical Stage and Biopsy Gleason Sum to Predict the Pathologic Stage at Radical Prostatectomy in the New Millennium. European Urology, 2007, 52, 1067-1075.	1.9	19
123	The presence of prostate cancer on saturation biopsy can be accurately predicted. BJU International, 2010, 105, 636-641.	2.5	19
124	Higher perioperative morbidity and inâ€hospital mortality in patients with endâ€stage renal disease undergoing nephrectomy for nonâ€metastatic kidney cancer: a populationâ€based analysis. BJU International, 2012, 110, E183-90.	2.5	19
125	Short-Term Outcome and Morbidity of Different Contemporary Urethroplasty Techniquesâ€”A Preliminary Comparison. Journal of Endourology, 2013, 27, 925-929.	2.1	19
126	Risk-Adjusted Hazard Rates of Biochemical Recurrence for Prostate Cancer Patients after Radical Prostatectomy. European Urology, 2009, 55, 412-421.	1.9	18

#	Article	IF	Citations
127	Predictive Value of Prostate-specific Antigen Expression in Prostate Cancer: A Tissue Microarray Study. Urology, 2009, 74, 1169-1173.	1.0	18
128	Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 81.e17-81.e24.	1.6	18
129	Inflammatory prognostic markers in clear cell renal cell carcinoma â€“ preoperative <scp>C</scp>â€reactive protein does not improve predictive accuracy. BJU International, 2012, 110, E771-7.	2.5	17
130	Extended Pelvic Lymph Node Dissection Does Not Affect Erectile Function Recovery in Patients Treated with Bilateral Nerveâ€Sparing Radical Prostatectomy. Journal of Sexual Medicine, 2012, 9, 2187-2194.	0.6	17
131	Development and internal validation of preoperative transition zone prostate cancer nomogram. Urology, 2006, 68, 1295-1300.	1.0	16
132	Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer. BJU International, 2007, 99, 1404-1408.	2.5	16
133	Effect of autologous blood transfusion on the rate of biochemical recurrence after radical prostatectomy. BJU International, 2007, 100, 1249-1253.	2.5	16
134	Prediction of Pathological Stage is Inaccurate in Men with PSA Values above 20ng/mL. European Urology, 2007, 52, 1374-1380.	1.9	16
135	Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. World Journal of Urology, 2012, 30, 807-814.	2.2	16
136	Holmium Laser Enucleation of the Prostate Is Safe in Patients with Prostate Cancer and Lower Urinary Tract Symptomsâ€"A Retrospective Feasibility Study. Journal of Endourology, 2014, 28, 335-341.	2.1	16
137	Older patients suffer from adverse histopathological features after radical cystectomy. International Journal of Urology, 2011, 18, 576-584.	1.0	15
138	Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1716-1724.	1.6	15
139	North American Populationâ€Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer. Prostate, 2017, 77, 542-548.	2.3	15
140	256â€<scp>MDCT</scp> for evaluation of urolithiasis: Iterative reconstruction allows for a significant reduction of the applied radiation dose while maintaining high subjective and objective image quality. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 283-290.	1.8	14
141	Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma. World Journal of Urology, 2013, 31, 847-853.	2.2	13
142	Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent. International Urology and Nephrology, 2013, 45, 1561-1567.	1.4	13
143	Concomitant Seminal Vesicle Invasion in pT4a Urothelial Carcinoma of the Bladder with Contiguous Prostatic Infiltration is an Adverse Prognosticator for Cancer-Specific Survival after Radical Cystectomy. Annals of Surgical Oncology, 2014, 21, 4034-4040.	1.5	13
144	Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients. BJU International, 2012, 110, 1714-1720.	2.5	12

#	Article	IF	Citations
145	Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer. BJU International, 2006, 98, 50-53.	2.5	11
146	Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer. Pathology, 2012, 44, 448-452.	0.6	11
147	Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy. Canadian Urological Association Journal, 2014, 8, 75.	0.6	11
148	External Validation of a Preoperative Nomogram for Prediction of the Risk of Recurrence After Radical Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2010, 77, 788-792.	0.8	9
149	The Search for Biomarkers of Metastatic Seminoma. Journal of Urology, 2013, 190, 1046-1051.	0.4	9
150	From Gene to Clinic: TMA-Based Clinical Validation of Molecular Markers in Prostate Cancer. Methods in Molecular Biology, 2010, 664, 177-189.	0.9	9
151	Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 47.e1-47.e8.	1.6	8
152	The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: Which markers matter and how should they be used?. World Journal of Urology, 2014, 32, 871-880.	2.2	8
153	Biopsies Performed at Tertiary Care Centers are Superior to Referral Biopsies in Predicting Pathologic Gleason Sum. Journal of Endourology, 2008, 22, 533-538.	2.1	7
154	A comparative assessment of active surveillance for localized prostate cancer in the community versus tertiary care referral center. World Journal of Urology, 2014, 32, 891-897.	2.2	7
155	Super early detailed assessment of lower urinary tract symptoms after holmium laser enucleation of the prostate (HoLEP): a prospective study. World Journal of Urology, 2020, 38, 3207-3217.	2.2	7
156	Reply to Juan Moroteâ€™s Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. Eur Urol 2009;56:659â€“68. European Urology, 2010, 57, e2-e3.	1.9	6
157	Differences in histopathological and biochemical outcomes in patients with low Gleason score prostate cancer. BJU International, 2010, 105, 818-823.	2.5	6
158	Predicting the risk of lymph node invasion during radical prostatectomy using the European association of urology guideline nomogram: A validation study. European Journal of Surgical Oncology, 2012, 38, 624-629.	1.0	6
159	Assays for Prostate Cancer. Molecular Diagnosis and Therapy, 2013, 17, 1-8.	3.8	6
160	Prediction of metastatic status in non-seminomatous testicular cancer. World Journal of Urology, 2014, 32, 1205-1211.	2.2	6
161	A Comparative Review of Apomorphine Formulations for Erectile Dysfunction. Drugs and Aging, 2006, 23, 309-319.	2.7	5
162	The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy. Biomarkers in Medicine, 2013, 7, 843-850.	1.4	5

#	Article	IF	Citations
163	Reduced membranous MET expression is linked to bladder cancer progression. Cancer Genetics, 2014, 207, 147-152.	0.4	5
164	Prediction of the Risk of Harboring Prostate Cancer by a Prebiopsy Nomogram Based on Extended Biopsy Protocol. Urologia Internationalis, 2013, 90, 306-311.	1.3	4
165	Prognostic impact of infiltration of the vagina and/or uterus in women undergoing anterior pelvic exenteration for urothelial carcinoma of the bladder: results of a contemporary multicentre series. World Journal of Urology, 2015, 33, 343-350.	2.2	4
166	Prediction of Complications in Radical Prostatectomy Prostate Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes. Urologia Internationalis, 2019, 102, 51-59.	1.3	4
167	Reply to Carsten Stephan et alâ€™s Letter to the Editor re: Felix K.-H. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael W. Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial Biopsy Outcome Predictionâ€"Head-to-Head Comparison of a Logistic Regression-Based Nomogram versus Artificial Neural Network. Eur Urol 2007;51:1236â€“43. European Urology, 2007, 51, 1448.	1.9	2
168	Reply. BJU International, 2013, 111, E20-1.	2.5	2
169	Prostate imagingâ€"the future is now: current concepts and future potentials. World Journal of Urology, 2014, 32, 843-845.	2.2	2
170	Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection. World Journal of Men?s Health, 2020, 38, 32.	3.3	2
171	[18F]FLUOROCHOLINE COMBINED IN-LINE PET-CT SCAN FOR DETECTION OF LYMPH-NODE METASTASIS PRIOR TO RADICAL PROSTATECTOMY: RESULTS FROM A PROSPECTIVE HISTOLOGY BASED STUDY. Journal of Urology, 2008, 179, 49-49.	0.4	1
172	Does Low-Risk Prostate Cancer Detection Change With Repeat Biopsies?. European Urology, 2012, 61, 230-231.	1.9	1
173	Reply to Ian Beckley and Masood A. Khanâ€™s Letter to the Editor re: Felix K.-H. Chun, Thomas Steuber, Andreas Erbersdobler, et al. Development and Internal Validation of a Nomogram Predicting the Probability of Prostate Cancer Gleason Sum Upgrading Between Biopsy and Radical Prostatectomy Pathology. Eur Urol 2006;49:820â€“26. European Urology, 2007, 52, 1271.	1.9	0
174	Editorial Comment on: Preliminary Results of a Novel Method to Estimate the Probability of Prostate Cancer in Men with Elevated Serum PSA Values. European Urology, 2008, 54, 702.	1.9	0
175	NERVE-SPARING RADICAL PROSTATECTOMY DOES NOT UNDERMINE THE RATE OF BIOCHEMICAL RECURRENCE IN CAREFULLY SELECTED PATIENTS WITH PATHOLOGICALLY CONFIRMED EXTRACAPSULAR EXTENSION. Journal of Urology, 2008, 179, 646-647.	0.4	0
176	LONG TERM OUTCOME OF PATIENTS WITH POSITIVE LYMPH NODES DURING RADICAL PROSTATECTOMY: SURVIVAL BENEFIT OF PATIENTS WITH COMPLETED VS. ABANDONED SURGERY. Journal of Urology, 2008, 179, 252-252.	0.4	0
177	In Reply. Deutsches Ärzteblatt International, 2015, 112, 758.	0.9	0